MedTrace Logo

A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

NCT02759250 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-08-08

No results posted yet for this study

Summary

To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).

Conditions

Interventions

DRUG

ARGX-110

Sponsors & Collaborators

Principal Investigators

  • Sylvie Rottey, MD · UZG - Universitair Ziekenhuis Gent

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-04-25
Completion
2018-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02759250 on ClinicalTrials.gov